AMSTERDAM, The Netherlands, September 11, 2013 /PRNewswire/ --
~ 67% survival demonstrated after 5 years and no transplant related mortalities ~
Manfred Ruediger , CEO of Kiadis Pharma , gives more information on ATIR ™ and the five-year follow-up data in a video available on http://www.kiadis.com
Kiadis Pharma B.V. , a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that the five-year follow-up of patients with high-risk malignancies from its Phase I/II clinical study confirms long-term safety and efficacy of ATIR™ over a broad dose range. ATIR™ is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for patients who do not have a standard of care stem cell donor available. The results demonstrate proof of concept and show that ATIR™ infusion after a T-cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) provides immune protection shortly after the transplantation and improves long-term outcome in high-risk patients with very poor prognosis.Not only does the study confirm that ATIR™ provides an effective treatment for patients for whom a standard of care stem cell donor is not available, the long term survival even seems to compare favorably to patients who do have a standard of care matched unrelated donor available. The overall survival of patients with high-risk malignancies in the Phase I/II study who received an efficacious dose of ATIR™ was 78% and 67% after one and five years, respectively. Data from the Center for International Blood & Marrow Transplant Research (CIMBTR) show that the one (and five) year survival of patients with acute myeloid leukemia (AML) who do have a standard of care matched unrelated donor available, varies from 65% (and 35%) in low-risk patients to 45% (and 20%) in high-risk patients, respectively.